By Adam Clark

GlaxoSmithKline PLC (GSK.LN) said Thursday it has received more positive data from its DREAMM-1 study of patients with multiple myeloma, the second-most common blood cancer in the U.S.

The pharmaceutical company said 60% of patients with relapsed/refractory multiple myeloma who received GSK2857916, an antibody drug conjugate, achieved an overall response rate. GlaxoSmithKline said this rate was identical to the result in its interim analysis, after more than a year of follow-up.

The number of patients achieving a complete response increased to 15% over the one-year follow-up period and the median progression-free survival rate was 12 months, up from 7.9 months previously, GlaxoSmithKline said.

"We are aggressively advancing this potential new medicine and plan to have pivotal data to support its filing by the end of this year," GlaxoSmithKline's Hal Barron said.

Write to Adam Clark at adam.clark@dowjones.com

(END) Dow Jones Newswires

March 21, 2019 12:32 ET (16:32 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Gsk.
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Gsk.